CCL2 and neoplasm: M2 TAMs support tumor progression through the release of immunosuppressive (i.e., CCL2 and IL-10), proangiogenic (i.e., IL-8 and VEGF), and tissue remodeling (i.e., MMP-2 and MMP-9) factors.